Early Caffeine Therapy for Preterm Infants: Timing and Clinical Outcomes

Caffeine therapy for premature babies reduces the risk of long-term lung disease and apnea when administered within the first 72 hours of life, but clinical evidence remains uncertain regarding the precise timing and indications for starting the treatment. According to cochrane.org, researchers analyzed 11 studies involving 774 infants published between 2014 and 2023 to evaluate how different timeframes and clinical reasons affect survival and health outcomes in neonatal intensive care units.

While the medication is widely used to manage breathing pauses and prevent mortality, experts emphasize that upcoming trials must examine varied schedules to establish definitive care standards. The evidence is current to April 23, 2025, according to cochrane.org, highlighting a critical need for standardized protocols in neonatal medicine.

Caffeine Therapy Within 72 Hours Reduces Apnea Risk

Researchers evaluated caffeine administration across multiple distinct timeframes and clinical scenarios to determine optimal delivery windows for vulnerable newborns. Studies compared caffeine given within two hours of life against treatment administered between two and 24 hours, as well as doses given within 72 hours versus after 72 hours. According to cochrane.org, the evidence remains very uncertain for outcomes reported in those specific early comparisons.

However, initiating therapy within 72 hours of life is likely to reduce the risk of both apnea and long-term lung disease when compared against treating infants only after symptoms appear. Data indicates that starting caffeine while an infant is on mechanical ventilation may greatly reduce required ventilation time and lower the risk of long-term lung disease compared to waiting until the breathing tube is removed.

Preventing Hyperkalemia in Preterm Infants

Additional clinical research expands on the benefits of early intervention by examining specific electrolyte disturbances in very preterm infants. In a single-center retrospective study conducted at the Kawaguchi Municipal Medical Center NICU in Japan, investigators evaluated 33 preterm infants born between 25 and 29 weeks of gestation between January 2019 and August 2020. Published in Pediatrics International, the study divided participants into a control group and an early caffeine group. Researchers concluded that prophylactic early caffeine therapy effectively prevents severe hyperkalemia within the first 72 hours of life for high-risk preterm infants. Despite documented benefits in specific clinical scenarios, significant knowledge gaps persist across neonatal care practices. Cochrane.org reported that no completed studies have compared caffeine started in infants with minimal symptoms directly against caffeine initiated during serious apnea episodes that require physical stimulation or ventilation support. None of the reviewed trials reported data on intermittent hypoxemia events. To address these lingering uncertainties, researchers have identified seven ongoing clinical trials examining caffeine administration parameters. The results of these upcoming studies are expected to clarify optimal treatment thresholds and potentially reshape clinical guidelines for neonatal intensive care units worldwide.

More on this story: Vestibular Stimulation for Premature Babies: Effects on Development and Health